FGF21

Overview

Fibroblast growth factor 21 (FGF21) is a secreted protein and endocrine metabolic regulator with important roles in energy homeostasis, lipid metabolism, glucose handling, and adaptive stress responses. In biomedical research, it is often discussed as a hepatokine because the liver is a major source of circulating FGF21, and it has been linked to insulin sensitivity, body weight regulation, fat mass, and broader metabolic control. Its biological effects are commonly considered in the context of metabolic dysfunction–associated steatotic liver disease, obesity, and type 2 diabetes, where it is studied as both a mechanistic mediator and a therapeutic target.

FGF21 is also notable for its integration into multi-hormone and tissue-crosstalk pathways. Recent work has examined its interaction with adiponectin in a PPARα-FGF21-adiponectin axis, its relationship to growth differentiation factor 15 and metformin-related stress signaling, and its processing by fibroblast activation protein alpha (FAP), which may alter circulating substrate availability. In experimental settings, FGF21 has been combined with gene therapy, antibody-based platforms, hydrogels, and incretin-related strategies such as GLP-1 receptor agonism and GIPR antagonism, reflecting its broad therapeutic interest in metabolic disease and tissue repair.

Recent Publications Summary

• In metabolic liver disease research, baicalein was reported to alleviate hepatic lipid metabolism disorders by activating the PPARα-FGF21-adiponectin axis, supporting crosstalk between the liver and adipose tissue. The study specifically proposed that its mechanism in ameliorating MAFLD-associated lipid disorders involved activation of the fibroblast growth factor 21 (FGF21)-adiponectin axis, linking FGF21 to coordinated regulation of hepatic and adipose metabolism 41967776Apr.

• In a gene therapy context, muscle-directed adeno-associated viral (AAV) vector-mediated FGF21 delivery extended health span and lifespan in aged and geriatric male and female mice, with sustained benefits across multiple organs. This study positions FGF21 as a systemic modifier of aging-associated physiology and tissue adaptation, and it explicitly frames FGF21 as a candidate for whole-body metabolic and longevity-related intervention 42231578Jun.

• A trispecific peptibody was engineered to combine GLP-1 receptor agonism, GIPR antagonism, and FGF21 pathway activation in a diet-induced obesity model. The rationale was to address the limitations of current obesity pharmacology by integrating complementary endocrine mechanisms, with FGF21 serving as one arm of a multi-target strategy that also involved Glucagon-like peptide-1 receptor signaling and GIPR modulation 42372355Jun.

• Bioactivity-guided isolation of diarylpentanoids from Rhamnoneuron balansae identified a compound that inhibited adipogenesis, promoted lipolysis, and induced thermogenesis and metabolic reprogramming through FGF21 and UCP1. In this setting, FGF21 was associated with anti-adipogenic and pro-thermogenic effects, suggesting involvement in energy expenditure and remodeling of fat-cell biology 42229863Jun.

• In a review of metabolic dysfunction–associated steatotic liver disease, FAP was proposed to influence disease progression by proteolytically affecting circulating substrates including FGF21 and α2-antiplasmin. This places FGF21 within a broader protease-substrate network relevant to liver disease biology and highlights FAP as a potential regulator of FGF21 bioavailability or activity 42233208Jun.

• A multifunctional self-contracting thermosensitive hydrogel incorporating FGF21 and molybdenum nanodots was developed to promote diabetic wound repair by reprogramming lipid metabolism and restoring energy metabolism homeostasis. The study used FGF21 as a bioactive component intended to correct lipid metabolism abnormalities in the wound microenvironment, supporting tissue repair in diabetes-associated impaired healing 41812869Mar.

• Combination gene therapy using AAV-based vectors was reported to ameliorate the phenotype of type 2 diabetes in diet-induced obese and db/db mice. Within this work, FGF21 was highlighted as a hepatokine that has gained attention for the treatment of metabolic disorders, reinforcing its role as a therapeutic candidate in insulin resistance, obesity, and glucose dysregulation 42011518Apr.

• A human study examining metformin found increased glycolysis and the stress-induced cytokine GDF15, but not FGF21. The authors noted that the tissue source responsible for GDF15 release and whether this is paralleled by induction of another, mainly liver-derived, stress-responsive cytokine, FGF21, remained unclear, indicating that metformin’s acute signaling effects do not necessarily include measurable FGF21 induction in humans 41928890Apr.

What Changes, What Holds

1. Baicalein adds another upstream route into the FGF21-adiponectin axis
REINFORCES Activating the PPARα-FGF21-adiponectin axis fits the established view of FGF21 as a mediator of hepatic-adipose crosstalk in metabolic liver disease. The new work does not displace the baseline mechanism; it sharpens it by placing a small-molecule natural product upstream of that axis in MAFLD-associated lipid disorder control 41967776Apr.

2. Muscle-targeted FGF21 delivery supports systemic aging-related benefits
NEW DIRECTION AAV-mediated delivery extends FGF21 beyond its established metabolic roles into longevity biology, which the Overview does not yet cover. The consequence is not a contradiction but an expansion: FGF21 now appears capable of modifying age-associated physiology across multiple organs, though the evidence remains preclinical and would need replication and mechanistic clarification before aging use could be generalized 42231578Jun.

3. FGF21 can be built into multi-hormone anti-obesity strategies
REINFORCES Combining FGF21 activation with GLP-1 receptor agonism and GIPR antagonism extends the established therapeutic interest in obesity and metabolic disease without changing FGF21’s basic role. The important point is strategic rather than conceptual: FGF21 remains one arm of a broader endocrine design, supporting the baseline picture of it as a modular metabolic target rather than a stand-alone replacement for incretin-based therapy 42372355Jun.

4. FGF21 is linked to anti-adipogenic and thermogenic remodeling of fat
REINFORCES Induction of FGF21 alongside UCP1-driven thermogenesis aligns closely with the Overview’s framing of FGF21 in energy homeostasis, lipid metabolism, and body weight regulation. The study strengthens the idea that FGF21 participates in adipose tissue remodeling toward higher energy expenditure, but it does not overturn the established account or introduce a new class of biology 42229863Jun.

5. FAP may control FGF21 availability in steatotic liver disease
NEW DIRECTION Proteolytic handling of FGF21 by FAP extends the baseline discussion from signaling and secretion to substrate processing and bioavailability in metabolic dysfunction–associated steatotic liver disease. That is a new regulatory layer rather than a contradiction: the Overview already notes FAP as relevant to FGF21 processing, and this work makes the liver-disease implication more explicit 42233208Jun.

6. FGF21-containing hydrogel platforms extend its use to diabetic wound repair
NEW DIRECTION Local delivery for wound healing goes beyond the Overview’s focus on systemic metabolic regulation, adding a tissue-repair application in diabetes-associated impaired healing. The finding broadens how FGF21 may be used, but it does not challenge its established metabolic functions; instead, it places FGF21 in a biomaterials context aimed at restoring lipid and energy balance in the wound microenvironment 41812869Mar.

7. FGF21 remains a credible adjunct target for diabetes therapy in combination gene delivery
REINFORCES Amelioration of type 2 diabetes phenotype with AAV-based combination therapy reinforces the established view of FGF21 as a therapeutic candidate in insulin resistance, obesity, and glucose dysregulation. The work does not add a new biological role; it supports the baseline claim that FGF21 is being pursued as a translational metabolic intervention, now within a multi-gene delivery framework 42011518Apr.

8. Human metformin signaling does not consistently induce circulating FGF21
NEW DIRECTION A metformin-associated rise in GDF15 without measurable FGF21 tempers the idea that stress-responsive cytokine induction necessarily includes this hepatokine in humans. The Overview already links FGF21 to metformin-related stress signaling, so this negative result matters: it suggests that, at least acutely, the metformin-GDF15 axis may be separable from FGF21 induction and that human regulation may be more selective than preclinical models imply 41928890Apr.

Overview update candidates: FGF21 as a candidate for systemic aging/longevity intervention; FGF21 in diabetic wound repair via biomaterial delivery; FAP as a regulator of FGF21 bioavailability in steatotic liver disease; lack of acute human FGF21 induction after metformin.